Axsome Therapeutics Inc

NASDAQ:AXSMUnited States

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in developing and delivering therapies for central nervous system (CNS), conditions that have limited treatment options. The Company's two commercial products and development programs are Auvelity and Sunosi. Auvelity (dextromethorphan-bupropion) is an oral, N-methyl-D-aspartate (NMDA) receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder (MDD). Sunosi (solriamfetol) is an oral medication indicated for the treatment of excessive daytime sleepiness (EDS), in patients with narcolepsy or obstructive sleep apnea. AXS-05 is an oral, investigational NMDA receptor antagonist with multimodal activity under development for the treatment of Alzheimer's disease agitation (AD agitation) and smoking cessation. AXS-07 is an oral, rapidly absorbed, multi-mechanistic, investigational medicine under development for the acute treatment of migraine.

Contact Information

Headquarters

One World Trade Center, 22Nd FloorNEW YORK, NY, United States 10007

Phone

212-332-3241

Fax

212-320-0245

Executives

Chairman of the Board, Chief Executive Officer, Founder, Interim Principal Financial Officer

Herriot Tabuteau

Chief Financial Officer

Nick Pizzie

Chief Operating Officer

Mark Jacobson

Executive Vice President - Product Strategy

Lori Englebert

Executive Vice President - Head of Commercial

Ari Maizel